Welcome to the Alaska Chapter of the American College of Cardiology
Welcome to the Alaska Chapter of the American College of Cardiology
|
16th Annual Cardiovascular Update Conference February 6th and 7th from 8:00 am - 5:00 pm For details visit: Registration Page |
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings
Latest in Cardiology from ACC.org
- ACC.26 Convocation Incoming President’s Address: Roxana Mehran, MD, FACCIncoming ACC President Roxana Mehran reflects on her journey, honors mentors and calls the cardiovascular community to lead with innovation, compassion and collaboration.
- ACC.26 Convocation Outgoing President’s Address: Christopher Kramer, MD, MACCOutgoing ACC President Christopher Kramer addresses scientific advances, global collaboration, advocacy wins and a year of leadership across the cardiovascular community.
- FUND-HF: Financial Support Improves Medication Adherence in Vulnerable PatientsProviding financial support early after hospital discharge to economically vulnerable patients with heart failure (HF) with reduced ejection fraction is feasible and significantly improved adherence to prescribed medications, according to results from the FUND-HF pilot trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC.
- IVUS-CHIP and OPTIMAL: IVUS-Guided vs. Angiography-Guided PCIWhen compared with angiography-guided PCI, IVUS-guided PCI was found to be not superior in patients with complex coronary arteries according to results from the IVUS-CHIP trial or in patients with unprotected left main coronary artery disease (LM-CAD) according to results from the OPTIMAL trial. Both trials were presented in a Late-Breaking Clinical Trial session at […]
- SirPAD: Sirolimus-Coated vs. Uncoated Balloons in Angioplasty For Infrainguinal Artery DiseaseFor patients with symptomatic infrainguinal artery disease, angioplasty with a sirolimus-coated balloon, compared with an uncoated balloon, reduced major adverse limb events (MALE) at one year, according to the SirPAD trial results presented during a Late-Breaking Clinical Trial session at ACC.26 and simultaneously published in NEJM.
